Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: -0.25 (-1.37%)
Spread: 1.00 (5.714%)
Open: 18.25
High: 19.00
Low: 17.85
Prev. Close: 18.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Manufacturing, supply & profit sharing agreement

1 Nov 2017 07:00

RNS Number : 1441V
OptiBiotix Health PLC
01 November 2017
 



OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Manufacturing, supply and profit sharing agreement with Knighton Foods

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it has entered into a manufacturing and supply agreement with Knighton Foods, ("Knighton"). The agreement grants Knighton an exclusive licence to manufacture and supply OptiBiotix's SlimBiome® weight management technology in the United Kingdom, in return for 50% of the profit, with an agreed cost of manufacture and minimum sales price per kilogramme.

 

Knighton, a wholly owned subsidiary of Premier Foods plc, is a leading producer of a wide range of high quality, value adding, functional powdered foods, specialist ingredients and finished products, to some of the countries major supermarkets, high street coffee houses, and best-known household brands. Knighton's advanced powder technology was key to developing an improved version of SlimBiome®, providing enhanced solubility and better product presentation, greatly improving flavour and mouthfeel.

 

SlimBiome®, a patented combination of natural ingredients developed by experts to provide hunger free weight loss, will be supplied by Knighton as a specialised functional ingredient, into a wide range of finished products for use in the retail, vending, and ingredients sectors. Knighton will use their best endeavours to promote and expand the supply of SlimBiome®, bringing it to the attention of product innovation teams across their wide range of customers.

 

This agreement, with one of the UK's leading specialist ingredients suppliers, is an important step in optimising the supply chain by leveraging Knighton's purchasing power, manufacturing efficiencies and partner network to scale up the manufacture and supply of SlimBiome®.  This is an important step to meet the needs of major UK retailers and exports of SlimBiome®, and SlimBiome® containing products to Tata, and potential new partners, in the Iarge consumer markets of India and the USA.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce the signing of a manufacturing, supply and profit sharing agreement with Knighton Foods. We chose Knighton due to their world leading expertise in adding value and differentiation to speciality powdered ingredients like SlimBiome®. Their development work greatly improved SlimBiome's solubility, taste and mouthfeel whilst reducing the overall cost of manufacture. We believe working with Knighton, and similar partners around the world, provides the best opportunity of meeting the requirements of major retailers and the growing interest we are seeing in SlimBiome® from partners worldwide."

 

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

Cairn Financial Advisers LLP (NOMAD)

Tel: 020 7213 0883

Liam Murray

 

FinnCap (Broker)

 

Tel: 020 7220 0500

Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)

Tony Quirke (Corporate Broking)

Walbrook PR Ltd

Tel: 020 7933 8780 or optibiotix@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

 

About OptiBiotix - www.optibiotix.com 

 

OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.

 

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 

 

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

 

About Knighton Foods www.knightonfoods.com

 

Knighton Foods, based in the U.K are a leading producer of high quality specialist powdered products. Their suite of processes includes, processing, blending and packaging capabilities ranging from portion controlled sachets to 1 ton bulk containers. 

Knighton's technical and R&D capabilities have been developed over 100+ years' and deliver value and functionality to ingredients and finished products, for use in the Retail, Out of Home, and Ingredients sectors. Examples of which can be found on the shelves of the UK's leading supermarkets in some of the most recognised consumer brands, and leading chains of fast food restaurants and coffee shops.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGREFLFXDBFBFBX
Date   Source Headline
20th Jul 20227:00 amRNSCommercial and scientific update
11th Jul 20227:00 amRNSJoint development agreement signed with Firmenich
1st Jul 20227:00 amRNSDirector Appointment and Director Dealing
28th Jun 20227:00 amRNSFinal Results
20th Jun 20227:00 amRNSProBiotix Health - Appointment of CEO
31st Mar 20227:01 amRNSAdmission of ProBiotix Health plc to AQSE
25th Mar 20222:36 pmRNSDirector/PDMR Shareholding
18th Mar 20222:00 pmRNSPrice Monitoring Extension
17th Mar 20227:00 amRNSIntention to list ProBiotix Health on AQSE
9th Mar 20227:00 amRNSExercise of warrants
1st Mar 20227:00 amRNSCommercial Appointments
28th Feb 20227:00 amRNSTrading Update
9th Feb 20227:00 amRNSCommercial and strategy update
1st Feb 20227:00 amRNSConsumer study of LPLDL in Cholbiome products
27th Jan 202210:38 amRNSExercise of Warrants
18th Jan 20227:00 amRNSPublication of third human study on LPLDL
7th Jan 20227:00 amRNSIssue of options
5th Jan 20227:00 amRNSOptiBiotix obtains BRC accreditation
15th Dec 20217:00 amRNSExclusive sales and distribution agreement
9th Dec 20217:00 amRNSLaunch of GoFigure range with Apollo Hospitals
1st Dec 202112:00 pmRNSInvestor presentation
1st Dec 20217:00 amRNSLaunch of LeanBiome with global nutrition leader
17th Nov 20217:00 amRNSFormation of OptiBiotix Health India
15th Nov 20214:59 pmRNSHolding(s) in Company
25th Oct 20217:00 amRNSSlimBiome® Approved by Health Canada
30th Sep 20217:00 amRNSHalf-year Report
1st Sep 20217:00 amRNSDirector/PDMR Shareholding
31st Aug 20217:00 amRNSDirector dealing
31st Aug 20217:00 amRNSInvestor update
10th Aug 20217:00 amRNSExtension of territories for Seed Health’s DS-01
5th Aug 20217:00 amRNSTrading and commercial update
9th Jul 202110:49 amRNSResult of AGM
6th Jul 20217:00 amRNSFurther sales expansion in Asia
17th Jun 20217:00 amRNSFinal Results
19th May 20212:00 pmRNSSkinBioTherapeutics plc shareholding
21st Apr 20217:00 amRNSDirector/PDMR Shareholding
16th Apr 20217:00 amRNSDirector’s Dealing
23rd Mar 20217:00 amRNSDirectorate Changes
17th Mar 20217:00 amRNSCommercial strategy update
2nd Mar 20217:00 amRNSDirector Appointment
24th Feb 20217:00 amRNSInvestor update
18th Feb 20217:00 amRNSStrategy and commercial update
2nd Feb 20217:00 amRNSProposed Director appointment
19th Jan 20217:00 amRNSNew appointments
12th Jan 20217:00 amRNSChange of broker
11th Jan 20217:00 amRNSResearch study
7th Jan 20214:41 pmRNSSecond Price Monitoring Extn
7th Jan 20214:36 pmRNSPrice Monitoring Extension
5th Jan 20217:00 amRNSDirectorate Change
9th Dec 20207:00 amRNSProposed Director appointment and Director change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.